Due to a production error, there was an error in the title. The corrected title appears above. The publisher apologizes for this mistake. The original version of this article has been updated.
. 2022 Jun 7;12:952053. doi: 10.3389/fonc.2022.952053
Erratum: Corrigendum: Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients With Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial
Frontiers Production Office1,*
1
Frontiers Media SA, Lausanne, Switzerland
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
✉
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
This article was submitted to Neuro-Oncology and Neurosurgical Oncology, a section of the journal Frontiers in Oncology
Received 2022 May 24; Accepted 2022 May 24; Collection date 2022.
Keywords: elderly patients, newly diagnosed glioblastoma, TTFields, Tumor Treating Fields, phase 3 clinical trial, efficacy and safety, quality-of-life, temozolomide
Copyright © 2022 Frontiers Production Office
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
PMCID: PMC9209944 PMID: 35747832